Curriculum Vitae

Personal information

Sarah Brophy

Work experience

1. Employer: Health Products Regulatory Authority

- Start Date: 102023
- End Date:
- Position: Pharmaceutical Assessor

2. Employer: ONK Therapeutics

- Start Date: 022021
- End Date: 062023
- Position: Senior Scientist/Team Lead

3. Employer: Autolus

- Start Date: 022019
- End Date: 012021
- Position: Scientist

4. Employer: Trinity College Dublin/ St.James's Hospital

- Start Date: 032018
- End Date: 012019
- Position: Postdoctoral Scientist

5. Employer: St.James's Hospital

- Start Date: 102016
- End Date: 022018
- Position: Molecular Scientist

6. Employer: Amgen

- Start Date: 052012
- End Date: 082012
- Position: Analyst (Intern)

Education and training

1. ATU Sligo/NIBRT

- Start Date: 092017
- End Date: 092018
- Qualification: Postgraduate Certificate in Biopharmaceutical processing

2. Trinity College Dublin

- Start Date: 092013
- End Date: 092017
- Qualification: PhD Haematology

3. Trinity College Dublin

- Start Date: 092014
- End Date: 092015
- Qualification: Postgraduate Certificate in Statistics

4. Trinity College Dublin

- Start Date: 092009
- End Date: 092013
- Qualification: BA Molecular Medicine

Additional information

Publications

Gurney M, O'Reilly E, Corcoran S, Brophy S, Krawczyk J, Otto NM, Hermanson DL, Childs RW, Szegezdi E, O'Dwyer ME. Concurrent transposon engineering and CRISPR/Cas9 genome editing of primary CLL-1 chimeric antigen receptor-natural killer cells. Cytotherapy. 2022 Nov;24(11):1087-1094.

Elizabeth S, Aidan K, David OB, Deirdre W, Sarah B et al. Low CD49d expression in newly diagnosed chronic lymphocytic leukaemia may be associated with high-risk features and reduced treatment-free-intervals. European Journal of Haematology. 2022 Nov;109(5):441-446.

Waldron C, O'Brien D, Brophy S, Perera K, Crotty GM, Dunlea E, Walsh A, Connolly M, Clifford R, O'Leary H, Khan A,

Lee G, Atkinson E, Le G, Gillett A, Bacon CL, McElligott AM, Quinn F, Vandenberghe E. Epidemiology of chronic lymphocytic leukaemia in an Irish subpopulation with total case ascertainment: an additional tool for health economic planning. Br J Haematol. 2022 Mar;196(5):e47-e49

Amet R, Previtali V, Mihigo HB, Sheridan E, Brophy S, Hante NK, Santos-Martinez MJ, Hayden PJ, Browne PV, Rozas I, McElligott AM, Zisterer DM. A novel aryl-guanidinium derivative, VP79s, targets the signal transducer and activator of transcription 3 signaling pathway, downregulates myeloid cell leukaemia-1 and exhibits preclinical activity against multiple myeloma. Life Sci. 2022 Feb 1;290:120236.

Projects

Memberships

Other Relevant Information